Compounds > razoxane
Page last updated: 2024-08-23

razoxane and Ovarian Neoplasms

razoxane has been researched along with Ovarian Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's3 (50.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albini, A; Anzà, C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM1
Brüggemann, RJ; Graaf, WT; Lesterhuis, WJ; Vos, FY1
Blessing, JA; Conroy, JF; Homesley, HD; Kessinger, A1
Benedetti Panici, P; Bonanno, G; Contu, G; De Vincenzo, R; Della Bitta, R; Ercoli, A; Mancuso, S; Pierelli, L; Scambia, G1
Bast, A; Boven, E; Grimbergen, JA; Kramer, K; Kuiper, K; van Acker, SA; van den Berg, DJ; van der Vijgh, WJ1
Kuz'mina, LP; Manikhas, GM; Protasov, DA; Zel'dovich, DR1

Trials

1 trial(s) available for razoxane and Ovarian Neoplasms

ArticleYear
[The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
    Voprosy onkologii, 1998, Volume: 44, Issue:6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Doxorubicin; Female; Heart; Humans; Ovarian Neoplasms; Razoxane; Treatment Outcome

1998

Other Studies

5 other study(ies) available for razoxane and Ovarian Neoplasms

ArticleYear
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
    Future cardiology, 2011, Volume: 7, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2011
Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment.
    Anti-cancer drugs, 2012, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Administration Schedule; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Razoxane

2012
Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
    Cancer treatment reports, 1984, Volume: 68, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperazines; Razoxane; Thrombocytopenia

1984
Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells.
    Gynecologic oncology, 1995, Volume: 57, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Ovarian Neoplasms; Razoxane; Tumor Cells, Cultured

1995
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Cardiomyopathies; Catechin; Chelation Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Electrocardiography; Female; Flavonoids; Flavonols; Free Radical Scavengers; Free Radicals; Humans; Hydroxyethylrutoside; Iron; Iron Chelating Agents; Kaempferols; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Ovarian Neoplasms; Quercetin; Razoxane; Rutin; Telemetry; Tumor Cells, Cultured; Weight Loss

1997